Diagnosing and Managing Polypoidal Choroidal Vasculopathy

Evidence-based strategies for diagnosis and therapeutic decision-making.

By: Giulia Gregori, MD, Jay Chhablani, MD

Retinal Physician March 1, 2026 Vol 23, Issue March-April 2026 Page(s): 6-8

Clinical Report: Diagnosing and Managing Polypoidal Choroidal Vasculopathy

Overview

Polypoidal choroidal vasculopathy (PCV) is a distinct choroidal vascular disorder characterized by recurrent subretinal hemorrhages. Diagnosis relies on multimodal imaging, particularly indocyanine green angiography (ICGA), while treatment strategies include anti-VEGF therapy and photodynamic therapy.

Background

PCV is significant due to its association with vision-threatening complications and its increasing recognition across diverse populations. Understanding the clinical features and management strategies is crucial for optimizing patient outcomes. The condition's overlap with age-related macular degeneration (AMD) complicates its diagnosis and treatment.

Data Highlights

No numerical data available in the source material.

Key Findings

List all established risk factors, including higher body mass index and hyperlipidemia.

Clinical Implications

Clinicians should consider PCV in patients with characteristic choroidal vascular lesions, especially when conventional treatments fail. A thorough understanding of multimodal imaging findings is essential for accurate diagnosis and effective management.

Conclusion

PCV remains a complex condition requiring careful diagnostic and therapeutic approaches. Ongoing research and consensus guidelines will aid in refining management strategies.

PentaVision

Retinal Physician